MYOV Myovant Sciences Ltd.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

$20.27  -0.53 (-2.55%)
As of 10/18/2021 16:00:02 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  Bermuda
IPO date:  10/27/2016
Outstanding shares:  92,077,860
Average volume:  498,243
Market cap:   $1,992,564,890
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    G637AM102
ISIN:        BMG637AM1024
Sedol:      
Valuation   (See tab for details)
PE ratio:   -8.83
PB ratio:   107.77
PS ratio:   29.72
Return on equity:   71.05%
Net income %:   -423.49%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy